文献速递免疫规划

双价前列腺癌疫苗与surgifoam配伍在PSA转基因小鼠中诱导抗原特异性效应T细胞

Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice.
PubMed 文献 · Vaccine · 2017-09-20

本研究在表达人PSA的转基因小鼠中评估双价腺病毒疫苗(Ad5-PSA+PSCA)与surgifoam配伍的免疫效果。结果显示该配伍可诱导强烈的PSA特异性效应CD8+ T细胞,并支持多次加强免疫使抗原特异性CD8+ T细胞显著增加,可能绕过中和抗体反应。

要点

  • 双价疫苗Ad5-PSA+PSCA与surgifoam配伍可在PSA转基因小鼠中诱导PSA特异性效应CD8+ T细胞。
  • 该配伍支持多次加强免疫,抗原特异性CD8+ T细胞显著增加。
  • 作者认为该配伍可绕过中和抗体反应并在自身抗原存在下诱导抗原特异性免疫应答。

核心结论

  • 双价前列腺癌疫苗(Ad5-PSA+PSCA)与surgifoam配伍可绕过中和抗体反应,从而允许多次加强免疫,并有助于在自身抗原存在下诱导抗原特异性免疫应答、维持长期效应CD8+ T细胞。

研究设计与样本

  • 在PSA转基因(PSA-Tg)小鼠中进一步表征双价疫苗(Ad5-PSA+PSCA)的免疫效果。

主要发现

  • 在PSA-Tg小鼠前列腺叶中,通过RT-PCR在mRNA水平和免疫组化在蛋白水平证实了PSA的表达。
  • 将双价疫苗与surgifoam配伍给予PSA-Tg小鼠,经IFN-γ分泌和体外细胞毒性T细胞实验检测,诱导了强烈的PSA特异性效应CD8+ T细胞。
  • 使用surgifoam与Ad5-PSA+PSCA疫苗配伍允许多次加强免疫,抗原特异性CD8+ T细胞显著增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We previously developed and characterized an adenoviral-based prostate cancer vaccine for simultaneous targeting of prostate-specific antigen (PSA) and prostate stem cell antigen (PSCA). We also demonstrated that immunization of mice with the bivalent vaccine (Ad5-PSA+PSCA) inhibited the growth of established prostate tumors. However, there are multiple challenges hindering the success of immunological therapies in the clinic. One of the prime concerns has been to overcome the immunological tolerance and maintenance of long-term effector T cells. In this study, we further characterized the use of the bivalent vaccine (Ad5-PSA+PSCA) in a transgenic mouse model expressing human PSA in the mouse prostate. We demonstrated the expression of PSA analyzed at the mRNA level (by RT-PCR) and protein level (by immunohistochemistry) in the prostate lobes harvested from the PSA-transgenic (PSA-Tg) mice. We established that the administration of the bivalent vaccine in surgifoam to the PSA-Tg mice induces strong PSA-specific effector CD8+ T cells as measured by IFN-γ secretion and in vitro cytotoxic T-cell assay. Furthermore, the use of surgifoam with Ad5-PSA+PSCA vaccine allows multiple boosting vaccinations with a significant increase in antigen-specific CD8+ T cells. These observations suggest that the formulation of the bivalent prostate cancer vaccine (Ad5-PSA+PSCA) with surgifoam bypasses the neutralizing antibody response, thus allowing multiple boosting. This formulation is also helpful for inducing an antigen-specific immune response in the presence of self-antigen, and maintains long-term effector CD8+ T cells.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Karan D. Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice. Vaccine. 2017. PMID: 28939158. doi:10.1016/j.vaccine.2017.09.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。